Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy

Trial Profile

Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Varlitinib (Primary) ; Capecitabine; Lapatinib
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 09 Feb 2017 Primary endpoint (Percentage change from baseline tumor size at Week 12) has been met, according to an ASLAN Pharmaceuticals Media Release.
    • 09 Feb 2017 Positive top-line results (n=50) published in an ASLAN Pharmaceuticals Media Release.
    • 11 Jul 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top